Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 9/20 | 0.40 |
| ▸ | CA2 | P00918 | 9/20 | 0.40 |
| ▸ | CA9 | Q16790 | 9/20 | 0.40 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20634547 | 0.94 | CA12 (0.42) | CA12CA2CA9CA1 | |
| SCHEMBL20635532 | 0.94 | CA12 (0.42) | CA12CA2CA9CA1 | |
| SCHEMBL24120437 | 0.85 | CA12 (0.38) | CA12CA2CA9CA1MEN1 | |
| SCHEMBL22193919 | 0.85 | CA12 (0.38) | CA12CA2CA9CA1MEN1 | |
| SCHEMBL22193988 | 0.85 | CA12 (0.38) | CA12CA2CA9CA1MEN1 | |
| SCHEMBL24109366 | 0.84 | CA12 (0.38) | CA12CA2CA9CA1KLK5 | |
| SCHEMBL20635300 | 0.81 | KLK5 (0.37) | KLK5 | |
| SCHEMBL24109099 | 0.81 | CA12 (0.34) | CA12CA2CA9CA1MEN1 | |
| SCHEMBL22194038 | 0.80 | LMNA (0.36) | CA12CA2CA9CA1KMT2A | |
| SCHEMBL22193978 | 0.78 | CA12 (0.37) | CA12CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| US-20210388017-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KP) | 2021-12-16 | — | — | US | disclosed |
| WO-2019008441-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2019-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210388017-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | VIP, ANTXR2, TNFRSF9 | CA12 60/4885CA2 225/4885CA9 247/4885 |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | CA12 60/4885CA2 225/4885CA9 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.